SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential Russell 1000 index inclusion, driving significant options activity and a high-volume surge that has intensified the ongoing conflict between bullish market participants and short sellers. Investors are closely watching for follow-through momentum and potential catalysts, including upcoming Q2 earnings and international clinical milestones, as they look to capitalize on the recent price action.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as a high-stakes binary battlefield, with investors closely monitoring the Phase 3 REGAL trial data and imminent survival event disclosures while short sellers face intensifying pressure from significant interest and elevated borrow rates. Community discourse centers on a potential short squeeze and buyout speculation, as retail traders debate the clinical implications of the trial's duration and its broader potential as a cancer treatment platform.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility and intense social media chatter as market participants react to the rapidly evolving geopolitical tensions between the U.S. and Iran. The community remains deeply divided, with many actively debating whether the recurring cycles of escalation and sudden diplomatic de-escalation are genuine developments or strategic market manipulation designed to influence sentiment ahead of the holiday week.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant patent expansion that secures exclusivity for its flagship drug, MIPLYFFA, through 2041. The community is actively discussing this move as a major catalyst that bolsters the company's long-term valuation and serves as a primary point of interest for potential M&A suitors.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense market debate as investors weigh the impact of institutional accumulation against concerns regarding potential liquidation risks tied to large corporate holdings. The community remains deeply divided, with bulls pointing to strong long-term holder resolve and potential regulatory catalysts, while bears focus on technical breakdowns and broader macroeconomic volatility.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is experiencing strong momentum and bullish sentiment as it breaks through key multi-year resistance levels, driven by its recent profitability inflection and aggressive growth guidance. The community is actively discussing the stock's significant recovery from previous lows, with many traders focused on the stock's potential for further expansion toward higher price targets while debating the balance between technical momentum and fundamental scaling.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is seeing renewed investor attention as the community focuses on its AI-driven credit underwriting as a potential infrastructure play, despite ongoing frustration with the stock's recent volatility and sensitivity to macro headwinds. Discussions are dominated by speculation over a potential short squeeze, upcoming product catalysts, and comparisons to other fintech peers in the sector.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors weigh strong institutional support and a series of analyst price target hikes against broader market volatility and concerns over energy grid demand. The community remains divided, with supporters pointing to long-term infrastructure contracts and AI data center expansion, while skeptics focus on potential short-term stock manipulation and power rate concerns in local communities.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently facing significant volatility driven by a major capital raise through convertible senior notes, which has fueled investor concerns over dilution despite the company's strong existing cash position. While the community is debating management's strategic intentions, active discussions remain focused on upcoming clinical trial data readouts and the broader long-term potential for gene editing as a disruptive healthcare theme.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending due to anticipation surrounding its ongoing commercial rollout of Rezdiffra and significant investor interest in potential M&A scenarios involving major industry players. Community sentiment remains mixed, with bullish supporters highlighting the company's first-mover advantage and pipeline expansion, while others debate the impact of high R&D spending and the competitive threat from emerging MASH treatments.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Home Depot (HD) Gains As Market Dips: What You Should Know

In the closing of the recent trading day, Home Depot (HD) stood at $348.86, denoting a +1.12% move from the preceding trading day.

Here's How Much $1000 Invested In Home Depot 20 Years Ago Would Be Worth Today

Home Depot (NYSE:HD) has outperformed the market over the past 20 years by 2.7% on an annualized basis producing an average annual return of 11.84%. Currently, Home Depot has a market capitalization of $334.58 billion.read more...

Home Depot vs. Lowe's: Which Stock Deserves Your Attention?

HD and LOW diverge on scale, Pro strength, valuation and stock performance as housing trends shape their investment appeal.

Can Margin Strength Offset Demand Challenges at Home Depot?

HD's margin resilience, Pro strength and strategic expansion may help buffer weak demand as housing pressures continue to weigh on spending.

Why Is Lowe's (LOW) Up 2.2% Since Last Earnings Report?

Lowe's (LOW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search The Home Depot, Inc. (HD): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Home Depot (HD). This makes it worthwhile to examine what the stock has in store.

Home Depot (HD) Up 5.4% Since Last Earnings Report: Can It Continue?

Home Depot (HD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Analyst Blog Highlights NVIDIA, Oracle, Home Depot, Catalyst Bancorp and Hour Loop

NVDA, ORCL and HD headline new analyst reports highlighting AI, cloud and retail growth drivers alongside key execution and market risks.

Top Analyst Reports for NVIDIA, Oracle & Home Depot

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Oracle Corporation (ORCL) and The Home Depot, Inc. (HD), as well as two micro-cap stocks, Catalyst Bancorp, Inc. (CLST) and Hour Loop, Inc. (HOUR).

Home Depot's FY26 Earnings Outlook: Signs of a Turnaround?

HD's positive comps, Pro momentum and digital growth signal early stabilization despite housing pressures and softer discretionary demand.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Why Did CHWY, HD, NCLH Stocks Hit 52-Week Lows Today?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

HDHome Depot, Inc.

Fundamentals

Latest HD News